Toxicity of Atenolol and Propranolol on Rat Heart Mitochondria

Enayatollah Seydi1,2, Yasaman Tabbati3, Jalal Pourahmad3

  • 1Department of Occupational Health and Safety Engineering, School of Health, Alborz University of Medical Sciences, Karaj, Iran.

Drug Research
|March 3, 2020
PubMed

Insights

Beta-blockers like propranolol and atenolol may harm heart mitochondria by increasing reactive oxygen species (ROS) and impairing function. This study reveals potential cardiotoxicity mechanisms linked to oxidative stress and mitochondrial damage.

Area of Science:

  • Cardiovascular Pharmacology
  • Mitochondrial Toxicology
  • Biochemistry

Background:

  • Beta-blockers, including propranolol and atenolol, are widely used for cardiac conditions.
  • Controversies exist regarding the impact of beta-blockers on reactive oxygen species (ROS) production.
  • Mitochondria are key sources of ROS and potential targets for drug-induced cardiotoxicity.

Purpose of the Study:

  • To investigate the effects of propranolol and atenolol on isolated heart mitochondria.
  • To evaluate specific markers of mitochondrial and cellular toxicity induced by these beta-blockers.

Main Methods:

  • Isolation of mitochondria from heart tissue.
  • Assessment of mitochondrial membrane potential (MMP).
  • Measurement of ROS levels, mitochondrial swelling, and cytochrome c release.
  • Evaluation of respiratory chain complex II activity.
  • Analysis of caspase-3 activity and ATP levels in cardiomyocytes.

Main Results:

  • Propranolol and atenolol exposure led to increased ROS levels in isolated heart mitochondria.
  • A significant collapse in MMP, mitochondrial swelling, and cytochrome c release were observed.
  • Disruption of respiratory chain complex II activity was evident.
  • Cardiomyocytes showed increased caspase-3 activity and decreased ATP levels.

Conclusions:

  • Propranolol and atenolol can induce cardiotoxicity through mechanisms involving mitochondrial dysfunction.
  • Oxidative stress and alterations in mitochondrial membrane integrity are implicated in this toxicity.
  • These findings highlight potential risks associated with beta-blocker use and warrant further investigation.

Related Concept Videos

Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
828
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.3K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.2K
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
19.4K